Stereotactic radiosurgery (SRS) is a key treatment for brain metastases, offering targeted therapy while minimizing damage to surrounding healthy brain tissue. However, optimizing dose escalation strategies remains a critical challenge to improving local tumor control without increasing neurotoxicity. This paper evaluates current literature on SRS dose escalation, its impact on tumor control, and strategies for mitigating associated risks. Through an analysis of recent studies from 2023, we examine the efficacy of dose adjustments and emerging treatment paradigms.